This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Aurora Cannabis Inc. (ACB) Flat As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Aurora Cannabis Inc. (ACB) closed at $4.76, marking no change from the previous day.
Epidolex Progresses: Will the Marijuana Drug Market Boom?
by Indrajit Bandyopadhyay
Cannabis (or marijuana) based medical products have the potential to become the next booming industry.
Cannabis Industry to Scale New Highs Amid Legalization Woes
by Nilanjan Gupta
Legalization will likely drive commercial distribution of cannabis and boost growth of companies operating in this space.
Aurora Cannabis Inc. (ACB) Flat As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Aurora Cannabis Inc. (ACB) closed at $5.27, marking no change from the previous day.
Options Traders Expect Huge Moves in Aurora Cannabis (ACB) Stock
by Zacks Equity Research
Investors need to pay close attention to Aurora Cannabis (ACB) stock based on the movements in the options market lately.
Aurora Cannabis Inc. (ACB) Reports Break-Even Earnings for Q4
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) delivered earnings and revenue surprises of 100.00% and 6.30%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Bonds, Apple Event, Uber and Lyft Bill & Buy Ciena Stock - Free Lunch
by Benjamin Rains
What's next for the Fed and increased corporate bond buying. Apple's (AAPL) highly anticipated event Tuesday. Aurora Cannabis (ACB) earnings. A California bill could shake up Uber (UBER) and Lyft (LYFT). And why Ciena (CIEN) is a Zacks Rank #1 (Strong Buy) stock right now - Free Lunch
Buy Aurora Cannabis (ACB) Stock Before Earnings, Despite Marijuana Volatility?
by Benjamin Rains
Despite growing sales and wider legalization, many pot stocks have been insanely volatile as Wall Street and investors try to wrap their heads around the marijuana industry. So should you think about buying "cheap" Aurora Cannabis (ACB) Stock before Q4 earnings?
Aurora Cannabis (ACB) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Cannabis revenue growth and improved gross margin are likely to aid Aurora Cannabis (ACB) in Q4 earnings.
What's in Store for Aurora Cannabis (ACB) in Q4 Earnings?
by Zacks Equity Research
Aurora Cannabis (ACB) expects revenues within $100-$107 million in fiscal Q4.
Aurora Cannabis Inc. (ACB) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) closed the most recent trading day at $5.59, moving -1.41% from the previous trading session.
Analysts Estimate Aurora Cannabis Inc. (ACB) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aurora Cannabis Inc. (ACB) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) closed at $5.58 in the latest trading session, marking a +0.18% move from the prior day.
Aurora Cannabis Inc. (ACB) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) closed the most recent trading day at $5.93, moving +1.54% from the previous trading session.
Canopy Growth (CGC) Earnings After The Bell: How High Can They Go?
by Daniel Laboe
Canopy is the clear leader in the marijuana space with a vastly diversified portfolio of cannabis products along with its STZ partnership.
HubSpot, Kraft Heinz, CNBS, Canopy Growth, Aurora Cannabis and GW Pharmaceuticals highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
HubSpot, Kraft Heinz, CNBS, Canopy Growth, Aurora Cannabis and GW Pharmaceuticals highlighted as Zacks Bull and Bear of the Day
Can European Expansion Aid Canopy Growth (CGC) Q1 Earnings?
by Zacks Equity Research
Canopy Growth's (CGC) recent acquisition of European companies will help it expand its production footprint into one of the most promising international regions.
Tilray to Report Earnings Today: Will It Top or Flop?
by Tirthankar Chakraborty
From global marijuana legalization to the rapidly increasing use of CBD as a wellness product, all of this should help Tilray witness an uptick in second-quarter revenues.
Cannabis Expert Tim Seymour's Favorite Pot Stocks and ETF
by Neena Mishra
CNBC's cannabis expert Tim Seymour explains why he launched his own Cannabis ETF.
Cannabis Expert Tim Seymour's Favorite Pot Stocks and ETF
by Neena Mishra
CNBC's cannabis expert Tim Seymour explains why he launched his own Cannabis ETF.
Cannabis, Ride Sharing and the never ending trade war, Paper Traders Ep 9
by Panel Of Zacks Experts
Erique and Danny Talk Through The Trade war impacts and recent earrings reports for Ride Sharing Companies Lyft and Uber.
ETFs in Focus as Consolidation Drives Marijuana Industry
by Sanghamitra Saha
Deals activity has been robust in the marijuana space, paving way for gains in these cannabis ETFs.
Factors Setting the Tone for Deere (DE) in Q3 Earnings
by Zacks Equity Research
Replacement demand for agricultural equipment and strong demand in construction likely to be conducive to Deere's (DE) third-quarter fiscal 2019 results.
Can Cannabis Therapy Drive Canopy Growth's (CGC) Q1 Earnings?
by Zacks Equity Research
Canopy Growth (CGC) expects to deliver a strong first-quarter fiscal 2020 on solid performance by its cannabis therapy business.
Tilray (TLRY) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports second-quarter 2019 results.